Shopping Cart
Remove All
Your shopping cart is currently empty
GW4869 (GW69A) is a selective and non-competitive inhibitor of neutral sphingomyelinase N-SMase (IC50=1 μM). GW4869 also inhibits exosome synthesis/release and is commonly used in exosome-related studies.Usually prepared as a suspension for experiments.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $48 | In Stock | In Stock | |
| 2 mg | $67 | In Stock | In Stock | |
| 5 mg | $87 | In Stock | In Stock | |
| 10 mg | $163 | In Stock | In Stock | |
| 25 mg | $345 | In Stock | In Stock | |
| 50 mg | $493 | In Stock | In Stock | |
| 100 mg | $625 | In Stock | In Stock | |
| 200 mg | $888 | - | In Stock |
| Description | GW4869 (GW69A) is a selective and non-competitive inhibitor of neutral sphingomyelinase N-SMase (IC50=1 μM). GW4869 also inhibits exosome synthesis/release and is commonly used in exosome-related studies.Usually prepared as a suspension for experiments. |
| Targets&IC50 | SMase:1 μM |
| In vitro | METHODS: Human breast cancer cells MCF-7 were pretreated with GW4869 (10 μM) for 30 min, then incubated with TNF (3 nM) for 6-24 h. Ceramide levels were detected by E. coli diacylglycerol kinase assay.
RESULTS: GW4869 significantly inhibited TNF-induced ceramide accumulation, and GW4869 inhibited N-SMase. [1] METHODS: Macrophage RAW264.7 was pretreated with GW4869 (10-20 μM) for 2 h, and then incubated with LPS (1 μg/mL) for 24 h. AchE activity was measured. RESULTS: After pretreatment of macrophages with 10 μM GW4869, LPS-triggered exocytosis was significantly attenuated in macrophages, and the activity of AChE was reduced by 22%. Treatment with 20 μM GW4869 further enhanced this attenuation. [2] |
| In vivo | METHODS: To detect in vivo activity, GW4869 (2.5 μg/g) was injected intraperitoneally into C57BL/6 mice, and LPS (25 μg/g) was injected 1 h later.
RESULTS: Pretreatment of mice with GW4869 attenuated LPS-triggered production of exosomes and pro-inflammatory cytokines in the blood, thereby reducing myocardial inflammation. [2] METHODS: To assay in vivo activity, GW4869 (200 μL of 0.3 mg/mL, 2-2.5 μg/g) was administered intraperitoneally to 5XFAD mice every two days for six weeks. RESULTS: GW4869 reduced amyloid plaque formation in vivo by blocking exosome secretion. [3] |
| Kinase Assay | B. cereu sphosphatidylcholine-PLC is incubated in the presence or absence of 10 μM GW4869 in a reaction mixture containing 100 mM Tris, pH 7.2, 25% glycerol, 20 mM p-nitrophenyl/phosphorylcholine, and production of p-nitrophenol is quantified spectrophotometrically at 410 nm. Protein phosphatase 2A from bovine kidney is incubated in the presence or absence of GW4869 in buffer containing 50 mM Tris, pH 7.4, 1 mM dithiothreitol, 100 μM MnCl2, and 20% glycerol, and phosphatase activity is measured[1]. |
| Cell Research | GW4869 is routinely stored at ?80?°C as a 1.5 mM stock suspension in Me2SO. Right before use, the suspension is solubilized by the addition of 5% methane sulfonic acid (MSA) (2.5 μl of 5% MSA in sterile double-distilled Water are added to 50 μL of GW4869 stock suspension). Cells are treated with GW4869 for 30 min and then TNF is added in 10 μL/well. At the indicated time points, 25 μL of MTT stock solution are added to each well and incubated at 37?°C in 5% CO2 for 3 h. The cell viability is using the MTT assay[1]. |
| Synonyms | GW69A, GW554869A, GW 4869 |
| Molecular Weight | 577.5 |
| Formula | C30H30Cl2N6O2 |
| Cas No. | 6823-69-4 |
| Smiles | Cl.Cl.O=C(Nc1ccc(cc1)C1=NCCN1)\C=C\c1ccc(\C=C\C(=O)Nc2ccc(cc2)C2=NCCN2)cc1 |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO: < 1 mg/mL (insoluble or slightly soluble), Suspension. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.